MARKET

CTLT

CTLT

Catalent Inc
NYSE
40.15
+1.30
+3.35%
Closed 17:41 12/01 EST
OPEN
38.74
PREV CLOSE
38.85
HIGH
40.27
LOW
38.44
VOLUME
2.11M
TURNOVER
0
52 WEEK HIGH
74.49
52 WEEK LOW
31.45
MARKET CAP
7.24B
P/E (TTM)
-7.6739
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CTLT last week (1127-1201)?
Weekly Report · 1h ago
Jim Cramer: Buy This Financial Stock, 'I Think They're High Quality'
Jim cramer says vishay intertechnology is "way too cheap" cramer also recommended buying abbott laboratories. Cramer said moelis & company has come down too much and recommended buying the same company.   Cramer was on cnbc's "mad money lightning round"
Benzinga · 3d ago
Catalent Inc: Current report
Press release · 6d ago
Weekly Report: what happened at CTLT last week (1120-1124)?
Weekly Report · 11/27 09:07
Weekly Report: what happened at CTLT last week (1113-1117)?
Weekly Report · 11/20 09:08
Wall Street Breakfast: What Moved Markets
Major stock market indexes eked out gains for a third straight week. Treasury yields continue to fall after surprisingly tame inflation data. Espn bet goes live in 17 u.s. States and competes with draftkings for online sports betting market share. The retail sales report was better than expected.
Seeking Alpha · 11/18 12:52
Why Analysts Are Bullish on Intel and Target Stock, Cautious on Advance Auto Parts
Mizuho securities upgrades intel to buy with a $50 price target. Advance auto parts is under significant financial strain, truist securities says. Guggenheim upgrades target to buy. Palo alto networks is downgraded to "outperform" by bmo research.
Barron‘s · 11/18 00:50
Lonza not planning to manufacture GLP-1 drugs: report
Lonza doesn't make peptides, a key ingredient in glp-1 weight-loss drugs. Lonza ceo says the company doesn't plan to participate in the market. Novo nordisk has reportedly hired lonza rivals to fill and finish the market for the drugs.
Seeking Alpha · 11/17 21:16
More
About CTLT
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.

Webull offers Catalent Inc stock information, including NYSE: CTLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTLT stock methods without spending real money on the virtual paper trading platform.